华兰生物
(002007)
| 流通市值：262.97亿 | | | 总市值：305.37亿 |
| 流通股本：15.74亿 | | | 总股本：18.27亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 867,612,696.57 | 4,379,196,621.38 | 3,490,648,261.92 | 1,652,707,481.28 |
| 营业收入 | 867,612,696.57 | 4,379,196,621.38 | 3,490,648,261.92 | 1,652,707,481.28 |
| 二、营业总成本 | 553,612,323.28 | 3,124,967,498.36 | 2,431,324,369.49 | 1,256,230,119.09 |
| 营业成本 | 379,309,429.12 | 1,688,240,780.68 | 1,334,425,541.24 | 814,929,187.59 |
| 税金及附加 | 8,384,548.4 | 38,345,990.56 | 28,469,899.53 | 17,388,160.46 |
| 销售费用 | 44,939,097.16 | 775,796,281.95 | 615,728,437.86 | 122,308,324.35 |
| 管理费用 | 54,147,464 | 296,249,466.25 | 249,830,845.9 | 165,209,089.59 |
| 研发费用 | 66,459,646.88 | 333,177,802.38 | 211,913,321.3 | 144,659,398.85 |
| 财务费用 | 372,137.72 | -6,842,823.46 | -9,043,676.34 | -8,264,041.75 |
| 其中:利息费用 | 2,739,142.52 | 12,946,391.85 | 11,378,340.78 | 8,208,245.71 |
| 其中:利息收入 | 2,399,982.27 | 20,429,035.28 | 20,817,849.92 | 16,747,510.16 |
| 加:公允价值变动收益 | 5,452,133.52 | 32,940,014.29 | 23,628,242.37 | 19,356,426.44 |
| 加:投资收益 | 38,443,296.73 | 137,517,910.98 | 103,562,812.67 | 67,879,421.27 |
| 资产处置收益 | -15,663.82 | 78,661.39 | 54,118.05 | 122,811.82 |
| 资产减值损失(新) | 1,046,468.97 | -74,225,065.72 | - | - |
| 信用减值损失(新) | 32,636,845.67 | 5,593,005.97 | 7,303,657.36 | 41,936,021.04 |
| 其他收益 | 5,890,180 | 23,448,748.14 | 28,025,139.33 | 13,185,880.95 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 397,453,634.36 | 1,379,582,398.07 | 1,221,897,862.21 | 538,957,923.71 |
| 加:营业外收入 | 7,715.21 | 3,248,126.52 | 3,283,673.68 | 3,251,422.48 |
| 减:营业外支出 | 12,888,031.45 | 44,217,846.75 | 26,420,816.26 | 8,291,892.69 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 384,573,318.12 | 1,338,612,677.84 | 1,198,760,719.63 | 533,917,453.5 |
| 减:所得税费用 | 60,741,950.07 | 183,142,885.59 | 187,601,764.85 | 85,142,182.97 |
| 六、净利润 | 323,831,368.05 | 1,155,469,792.25 | 1,011,158,954.78 | 448,775,270.53 |
| 持续经营净利润 | 323,831,368.05 | 1,155,570,296.32 | 1,011,259,458.85 | 448,875,774.6 |
| 终止经营净利润 | - | -100,504.07 | -100,504.07 | -100,504.07 |
| 归属于母公司股东的净利润 | 313,135,984.76 | 1,087,850,982.47 | 923,656,831.05 | 440,196,094.59 |
| 少数股东损益 | 10,695,383.29 | 67,618,809.78 | 87,502,123.73 | 8,579,175.94 |
| (一)基本每股收益 | 0.17 | 0.6 | 0.51 | 0.24 |
| (二)稀释每股收益 | 0.17 | 0.59 | 0.5 | 0.24 |
| 九、综合收益总额 | 323,831,368.05 | 1,155,469,792.25 | 1,011,158,954.78 | 448,775,270.53 |
| 归属于母公司股东的综合收益总额 | 313,135,984.76 | 1,087,850,982.47 | 923,656,831.05 | 440,196,094.59 |
| 归属于少数股东的综合收益总额 | 10,695,383.29 | 67,618,809.78 | 87,502,123.73 | 8,579,175.94 |
| 公告日期 | 2025-04-28 | 2025-03-29 | 2024-10-30 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |